www.science.org/doi/10.1126/...
“DCs from patients with systemic #lupus erythematosus that have variants in the ETV3 gene previously linked to the disease had lower expression of ETV3 compared with DCs from individuals that did not carry the allele. “
B cell-intrinsic role of IL-2 wherein IL-2-MAF axis promotes differentiation of CD25+ age-associated B cells toward a regulatory, IL-10-producing neuroprotective phenotype @cp-immunity.bsky.social
www.cell.com/immunity/ful...
Review @natrevrheum.nature.com
Mechanisms of fibrotic tissue remodelling: insights from systemic sclerosis
www.nature.com/articles/s41...
www.novartis.com/news/media-r...
👉“Ianalumab has potential to become first targeted treatment for this autoimmune disease with significant unmet need”
#Sjogren #Ianalumab
📖
“•Naive myelin-reactive B cells enter the brain and capture antigen
•B cells capturing antigen in the brain die by activation-induced cell death
•EBV protein LMP1 can rescue B cells from activation-induced cell death
•B cells rescued after antigen capture induce MS-like lesions”
#Bcell #Antigen
Spatial patterning of fibroblast TGFβ signaling underlies treatment resistance in rheumatoid arthritis
www.nature.com/articles/s41... @natimmunol.nature.com @harvardmed.bsky.social @flindersuniversity.bsky.social
www.jnj.com/media-center...
📝Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study.
#SLE #phase2
Pathogenic role of MIF receptor (CD74) expressing T cells in inflammatory arthritis @pnas.org @yalepress.bsky.social
www.pnas.org/doi/10.1073/...
Chinese Immune Multi-Omics Atlas @science.org
www.science.org/doi/10.1126/...
www.nature.com/articles/s41...
📖 CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial
“CASTLE suggests the feasibility, safety and efficacy of Zorpo-cel in three different autoimmune diseases and paves the way for conducting a pivotal study.”
#SLE #CART
Happy New Year 🎉
The last few weeks have been very chaotic as I prepared my move to the Netherlands 🛫🇳🇱. I’m very grateful for my new environment now and hope I can work hard on my new research project ☺️🔥
Let’s go, 2026 ✨
Review @natrevrheum.nature.com @georgearobinson.bsky.social
@ucl.ac.uk
Insights into the pathogenesis of childhood-onset SLE in the past decade
www.nature.com/articles/s41...
podcasts.apple.com/jp/podcast/t...
One of my favorite podcast is highlighting #lupus in this episode🎧Yay🧡
@immunologypodcast.com
Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus @thelancet.com
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
www.science.org/doi/10.1126/...
📖”This marks a critical point in B cell fate commitment, whereby CD21 down-regulation initiates EF B cell proliferation and differentiation, driving the rapid production of ASCs. “
#Bcell #SLE #lupus
www.nature.com/articles/s41...
📖 “Distinct autoreactive CD19– plasma cell subsets accumulate in lupus-prone mice”
#SLE #lupus #Bcell
www.science.org/doi/10.1126/...
“These EBV-infected B cells with antigen-presenting abilities had the capacity to activate autoreactive helper T cells, setting off a chain reaction where those T cells could activate other autoreactive B cells, including uninfected ones.”
#SLE #Bcell #EBV
www.science.org/doi/10.1126/...
“RA is characterized by pathological fibroblast-like synoviocytes (FLSs)... To address this, Huang et al. focused on the role of small nucleolar RNA, C/D box 3 (SNORD3), which is up-regulated by inflammatory modulators that are important in RA models.”
#arthritis
Review: Pathogenic drivers of lupus myocarditis and potential therapeutic targets @taejoonw.bsky.social
www.nature.com/articles/s12...
@natrevrheum.nature.com Cutaneous lupus erythematosus — from pathogenesis to targeted therapy @kahlenberglab.bsky.social
www.nature.com/articles/s41...
www.science.org/doi/10.1126/...
📖”Through a lineage-tracing approach, they detected conversion of synovial TH17 cells to CD44+ IFN-γ−IL-10− exTH17 cells, which are arthritogenic and cause joint inflammation independent of IL-17. “
#Th17 #arthritis
www.cell.com/immunity/abs...
📖 Highly functional and prolonged germinal center T follicular helper cell responses are associated with enhanced neutralizing antibody development
#Tfh #germinalcenter
TLR7 drives age-associated B cell formation in lupus through m6A demethylase FTO-mediated mitochondrial oxidation
www.science.org/doi/10.1126/...
🆕 Clinical Year in Review at #ACR25
By Dr. Bryant England @unmc.bsky.social
🔶 Review the most impactful studies in #Rheumatology from the past year!
❓ Any studies you would add to the list?
#RheumSky #MedSky #YearInReview
🆕 2025 ACR Guideline for Treatment of Systemic #Lupus Erythematosus 🦋
Just Released: Nov 3 #ACR25 🔥
🔸Review organ-specific treatment recommendations
🔸Steroid & HCQ Use Guidance
🔸Management of Comorbidities
➠ Read the Full Guideline here: acr.tw/47mkegj
#RheumSky #SLE #Rheumatology
S-TIR-ring up TLR7 and TLR9: signaling domain substitutions clarify the TLR paradox
www.jci.org/articles/vie...
@jci.org
www.jci.org/articles/vie...
Overview of the recommended management for systemic lupus erythematosus (SLE). This schematic illustrates the approach to SLE treatment, with organ-specific therapies presented in separate boxes and stratified by disease severity. The order of the medications in each box does not indicate preference unless noted otherwise. Lupus nephritis treatment is addressed in the 2025 American College of Rheumatology Guideline for the Screening, Treatment, and Management of Lupus Nephritis. ABBREVIATIONS: ACLE, acute cutaneous lupus erythematosus; SCLE, subacute cutaneous lupus erythematosus; CCLE, chronic cutaneous lupus erythematosus; CNI, calcineurin inhibitor (cyclosporin or tacrolimus); HCQ, hydroxychloroquine; CQ, chloroquine; CCB, calcium channel blockers; IL-1 blockade, Interleukin-1 blockade; IS, immunosuppressive therapy; IV CYC, intravenous cyclophosphamide; IVIG, intravenous immunoglobulins; LCV, leukocytoclastic vasculitis; MPAA, mycophenolic acid analogs; NSAIDs, non-steroidal anti-inflammatory drugs; PDE5i, phosphodiesterase type 5 inhibitors; PLEX, plasma exchange. FOOTNOTES: ** In CLE, switch HCQ to CQ with the intention of changing back to HCQ once the rash is under control. † Azathioprine may be used when pregnancy is planned. Based on the Voting Panel members’ clinical experience, anifrolumab has a more rapid onset of benefit and a greater likelihood of response than belimumab. ⁂ MPAA may be preferable over Azathioprine § Alternative agents such as leflunomide are occasionally used for those with arthritis ‖ Evidence for severe neurologic syndromes was largely limited to IV CYC
Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus
📄 Read the paper: acr.tw/47mkegj
ℹ️ See additional content and resources on this guideline at acr.tw/4mbHK4W
#Medsky #Rheumsky #Rheumatology
www.thelancet.com/journals/lan...
👉”Fc receptor blockade by nipocalimab 15 mg/kg significantly improved clinical disease activity versus placebo and was safe and well tolerated in participants with moderate-to-severe, active Sjögren's disease.”
#Sjogren #PhaseII
www.sciencedirect.com/science/arti...
📖 GZMK+CD8+ T cells target a specific acinar cell type in Sjögren's disease
#Sjogren #Tcell
www.nature.com/articles/s41...
📖 “The exonuclease PLD4 helps restrain activation of TLR7 and TLR9 by cleaving their ligands.
…identified loss-of-function variants in PLD4 in five patients with #SLE, linking disruption of this regulatory mechanism with systemic inflammation and #autoimmunity.”
